03 June, 2017
While looking at the Stock's Performance, ZIOPHARM Oncology, Inc. now shows a Weekly Performance of -11.71%, where Monthly Performance is -16.64%, Quarterly performance is -3.17%, 6 Months performance is -9.62% and yearly performance percentage is -21.06%.
ZIOPHARM Oncology (NASDAQ:ZIOP) traded down 2.29% during mid-day trading on Thursday, hitting $5.97. Price targets frequently change, depending on the outlook for a company's earnings. The lowest target is $100.0 while the high is $110.0.
Analysts on average have given a price target of $14.75 to ZIOPHARM Oncology, Inc. The firm is scheduled to report its next earnings report on Tuesday, August 8th. The Weekly and Monthly Volatility stands at 7.74% and 6.98%. The mean revenue estimate is $6.5M. Rating Scale; where 1.0 rating means Strong Buy, 2.0 rating signify Buy, 3.0 recommendation reveals Hold, 4.0 rating score shows Sell and 5.0 displays Strong Sell signal.
ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP), maintained return on investment for the last twelve months at -167.56, higher than what Reuters data shows regarding industry's average. They expect $0.50 earnings per share, down 3.85% or $0.02 from last year's $0.52 per share. The firm had revenue of $1.60 million for the quarter, compared to analyst estimates of $1.71 million. ZIOPHARM Oncology had a negative return on equity of 364.49% and a negative net margin of 2,276.89%. A 1 analysts rate it as either a buy or a strong buy, while0 believe that investors should either steer clear of ZIOPHARM Oncology, Inc.
A number of research firms have recently weighed in on ZIOP. Griffin Securities reissued a buy rating and issued a $23.00 price target (up from $21.00) on shares of ZIOPHARM Oncology in a research report on Friday, February 10th. Zacks Investment Research raised ZIOPHARM Oncology from a "sell" rating to a "hold" rating in a research note on Wednesday, April 26th. The stock of Silicon Laboratories (NASDAQ:SLAB) has "Buy" rating given on Thursday, October 27 by M Partners. $7's average target is 16.67% above currents $6 stock price.
TRADEMARK VIOLATION NOTICE: "Wynn Resorts, Limited (WYNN) Earning Somewhat Favorable Press Coverage, Analysis Finds" was posted by Stock Observer and is the property of of Stock Observer. If you are viewing this piece on another domain, it was illegally stolen and reposted in violation of USA & worldwide copyright legislation. The stock of ZIOPHARM Oncology Inc. It dropped, as 12 investors sold NMIH shares while 39 reduced holdings. Third Security LLC acquired a new stake in ZIOPHARM Oncology during the fourth quarter valued at approximately $51,946,000. National Planning Corp boosted its position in shares of ZIOPHARM Oncology by 8.7% in the fourth quarter. About shares traded. Silicon Laboratories (NASDAQ:SLAB) has risen 59.49% since May 31, 2016 and is uptrending. Its down 1.82% from 36.62 million shares previously. NY raised its stake in ZIOPHARM Oncology by 4.6% in the first quarter.
The Relative Volume of the company is 1.52 and Average Volume (3 months) is 1.38 million. California Public Employees Retirement System now owns 435,532 shares of the biotechnology company's stock worth $2,541,000 after buying an additional 213,166 shares during the period. Hedge funds and other institutional investors own 75.36% of the company's stock. Wells Fargo initiated the shares of ZIOP in report on Friday, December 4 with "Underperform" rating. (ZIOP) stock; watched recent volatility movements, they can see that shares have been recorded at 6.60% for the week, and 7.13% for the last month. Tracking the stock price in relation to moving averages as well as highs and lows for the year might assist with evaluating future stock performance.
